newsfilter
← Latest News
Business Wire·

Urovant Sciences® Receives "Best in Category" Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Presented at 2022 International Continence Society Conference

Interim 12-week analysis from the ongoing Phase 2a trial of an investigational novel gene therapy product, URO-902 (plasmid human cDNA encoding maxi-K channel), receives International Continence Society (ICS) recognition for "Best in Category Prize: O